B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis

BMC Pediatrics

Brian Sims¹  Jegen Kandasamy¹  Alain Cuna¹ 

[1] Department of Pediatrics, Division of Neonatology, University of Alabama at Birmingham, 619 S 19th St, Birmingham AL, 35249, USA

关键词: Outcome;    Prognostic factors;    Bronchopulmonary dysplasia;    Prematurity;   

Others  :  1138964
DOI  :  10.1186/1471-2431-14-68

 received in 2013-12-10, accepted in 2014-03-04,  发布年份 2014

【 摘 要 】

Background

B-type natriuretic peptide (BNP) is a strong predictor of mortality in adult patients with various forms of pulmonary hypertension (PH) and may be a strong prognostic marker in extremely low birth weight (ELBW) infants with bronchopulmonary dysplasia (BPD) associated PH as well. We sought to assess the relationship between BNP levels and all-cause mortality in a cohort of ELBW infants with BPD and PH.

Methods

We retrospectively identified ELBW infants with BPD and PH who had serum BNP levels measured as part of routine clinical care in the neonatal intensive care unit. Peak serum BNP levels were correlated with survival to discharge or death.

Results

Thirty-six ELBW infants (mean gestational age 26.0 ± 1.9 weeks and mean birth weight 740 ± 290 grams) with BPD and PH had available survival data and had serum BNP levels measured. Peak BNP level was significantly lower among infants who survived than among those who died (128 pg/ml, [IQR 23 to 463] vs. 997 pg/ml, [IQR 278 to 1770], P < 0.004). On multivariate Cox proportional hazard analysis, BNP predicted survival independent of age, gender, and BPD severity. Area under receiver operator characteristic analysis identified a BNP value of 220 pg/ml to have 90% sensitivity and 65% specificity in predicting mortality.

Conclusion

BNP estimation may be useful as a prognostic marker of all-cause mortality in ELBW infants with BPD associated PH.

【 授权许可】

   
2014 Cuna et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hislop AA, Haworth SG: Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol 1990, 9(3):152-161.
• [2]Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M: Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988, 112(1):67-72.
• [3]An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, Kim HS, Choi JH, Noh CI, Yun YS: Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010, 40(3):131-136.
• [4]Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA: Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011, 31(10):635-640.
• [5]Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N: Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012, 129(3):e682-e689.
• [6]Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC, Wynn RJ, Ryan RM: Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007, 27(4):214-219.
• [7]Kim GB: Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 2010, 53(6):688-693.
• [8]Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP: Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007, 120(6):1260-1269.
• [9]Collaro JM, Romer LH, Stuart BD, Coulson JD, Everett AD, Lawson EE, Brenner JI, Brown AT, Nies MK, Sekar P, Nogee LM, McGrath-Morrow SA: Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol 2012, 47(11):1042-1053.
• [10]Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339(5):321-328.
• [11]de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362(9380):316-322.
• [12]Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006, 98(4):525-529.
• [13]Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31(1):202-208.
• [14]Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102(8):865-870.
• [15]Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kurabayashi M: Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J 2010, 51(5):343-347.
• [16]Mauritz GJ, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, Eilers P, Bosboom J, Postmus PE, Westerhof N, Vonk-Noordegraaf A: Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011, 108(11):1645-1650.
• [17]Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 163(7):1723-1729.
• [18]Cuna A, Kandasamy J, Fineberg N, Sims B: B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatology 2013, 2013(3):33-36.
• [19]Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352(7):666-675.
• [20]Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH: Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008, 121(2):317-325.
• [21]Check J, Gotteiner N, Liu X, Su E, Porta N, Steinhorn R, Mestan KK: Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol 2013, 33(7):553-557.
• [22]Hines MH: Invited commentary. Ann Thorac Surg 2006, 81(1):234-235.
• [23]Rosenzweig EB, Feinstein JA, Humpl T, Ivy DD: Pulmonary arterial hypertension in children: diagnostic work-up and challenges. Prog Pediatr Cardiol 2009, 27(1):4-11.
• [24]DeFilippi CR, Seliger SL, Maynard S, Christenson RH: Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007, 53(8):1511-1519.
• [25]McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, Breathing Not Properly Multinational Study Investigators: B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing Not properly multinational study. Am J Kidney Dis 2003, 41(3):571-579.